In 2017, Domain Therapeutics and Pfizer signed a collaboration agreement to accelerate the validation of novel GPCR drug targets using bioSens-All™ (see press release)

Program description

Multi-target collaboration for rare diseases

  • Discovery
  • Candidate
  • Preclinical
  • Clinical

The multi-target drug discovery program aims at validating potential targets across a range of therapeutic indications by probing the structure-function relationships of various amino acid substitutions in each GPCRs.

The collaboration is based on our proprietary platform bioSens-All™ which enables to assess the impact of mutations on different signaling pathways engaged by GPCRs.

Other Programs

First-in-class mGluR3 PAM for Parkinson’s disease


First-in-class anti-GPCR antibody for immuno-oncology